Semaglutide is a single GLP-1 agonist
This fat accumulation can cause increased inflammation
This includes anyone who: Is pregnant or breastfeeding Is trying to get pregnant (men and women included) Is taking monoamine oxidase inhibitors, adrenergic neuron-blocking drugs, or other GLP-1 medications Has a history of drug abuse or dependence Has high blood pressure, even if its mild Has poor kidney function Has a history of heart disease Has glaucoma Has hyperthyroidism Has a personal or family history of certain thyroid cancers What to know about semaglutide Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus

CrossRef The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy Mingming Zhang, Han Chen, Huan Liu, Hong Tang Biomarker Research .2024;[Epub] CrossRef VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane The Lancet Gastroenterology & Hepatology .2024
Following crossover to HA + GSH-C4 (V3 to V6), directional increases were observed for several mediators, although these changes did not achieve statistical significance compared to baseline, mirroring the trends seen in clinical outcomes for this sequence
The MHRA has warned that, outside authorised clinical trials, products being sold in the UK claiming to contain retatrutide are likely to be illegal and potentially dangerous